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ABSTRACT
Four recent publications reported the role of PD-L1 expression on host versus malignant cells within the
tumor for PD-1/PD-L1 checkpoint blockade therapy. All four research groups harmoniously report: PD-L1
expressed by both host as well as tumor cells are capable of suppressing T cell functions. Thus, checkpoint




Within a time window of 2 mo in early 2017, four independent
research groups published papers in high impact journals advo-
cating a similar message using gene silencing technologies in
vivo. All groups investigated the role of PD-L1 expression on
different cell types within the tumor-microenvironment, in
terms of T cell inhibition and/or immune-checkpoint blockade
therapy (Fig. 1). Not only is this a tribute to the importance of
the PD-1/PD-L1 axis in tumor immunology, but also illustrates
the speed at which the oncoimmunology field is progressing.
In Cancer Immunology Research, Noguchi et al. used two
variants of an MCA-induced mouse tumor model that either
grow progressively or regress spontaneously.1 By overexpress-
ing or knocking out PD-L1, using CRISPR-Cas9, they described
how PD-L1 on tumor cells determines whether tumors prog-
ress or regress, by inhibiting the antitumor T cell response.
Tumors that were otherwise too immunogenic to establish,
were growing out rapidly by overexpression of PD-L1. Con-
versely, tumors growing out in immune competent mice were
spontaneously eradicated or slowed in their tumor-outgrowth
when PD-L1 was knocked out from tumor cells. In all these
cases, blocking PD-L1 with a therapeutic antibody had addi-
tional effect, indicating a role of PD-L1 on stromal cells.
In Nature Communications, Lau et al. used both PD-L1¡/¡
tumor cells, generated with CRISPR-Cas9, and a newly gener-
ated PD-L1 knockout mouse as a host, to study T cell inhibition
by PD-L1 in two commonly used mouse tumor models, MC38
and CT26.2 PD-L1 knockout variants of these tumors sponta-
neously regress or grow slower than WT counterparts, while
therapeutic PD-L1 blockade further extends survival, indicating
an additive role of PD-L1 on both tumor and host cells. Gene
expression analysis showed the strongest enrichment for T cell
immunity-related genes when PD-L1 was lacking on both
tumor cells and host cells. The authors describe several alterna-
tive immune escape mechanisms in outgrowing PD-L1
knockout tumors, including reduced MHC-I expression and
increased PD-L2 expression.
In the Journal of Experimental Medicine, Juneja et al.
emphasize that while both tumor and host cell PD-L1 expres-
sion can play a crucial role in T cell suppression and response
to blockade therapy, their exact relative contribution is context-
dependent, as it differed per tumor model in their experi-
ments.3 The authors used three different mouse tumor models
in host mice deficient for either PD-1 or for both PD-L1 and
PD-L2, as compared with WT hosts. Whereas B16 and BRAF.
PTEN tumors grew slower in both PD-1 deficient mice and
PD-L1 deficient mice, MC38 tumors only benefited from the
absence of host PD-1, indicating no relevant role for host PD-
L1 in MC38 tumor growth. The strong effect of therapeutic
PD-L1 blockade was therefore largely dependent on tumor cell-
expressed PD-L1, and could be mimicked by knocking out PD-
L1 selectively on tumor cells. The authors further argue that
PD-1 expression on T cells in tumors or tumor-draining lymph
nodes may well reflect recent activation and not necessarily a
dysfunctional state, especially when PD-1 ligands are lacking or
blocked at the target site.
Finally, in OncoImmunology, we have described a non-
redundant role of PD-L1 expression on tumor cells and host
cells.4 Using CRISPR-Cas9 technology, we created PD-L1
knockout variants of MC38 and CT26, the two most widely
used pre-clinical tumor models in tumor immunotherapy
research, which both grew out more slowly than WT tumors.
In straight-forward experiments, we show that blocking PD-L1
or PD-1 with therapeutic antibodies still has tumor-eradicating
effects on these tumors, indicating an additional role for PD-L1
on immune infiltrating cells within the tumor microenviron-
ment. T cell depletion studies emphasized the crucial role of
CD8 T cells in the antitumor effects of both the lack of PD-L1
on tumor cells and of blocking antibody therapy.
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Each study reveals, from a different angle, that PD-L1 on
tumor and host cells is involved in suppressing the antitu-
mor T cell response. All manuscripts show that in immuno-
competent mice, tumor cells grow out slower or regress
spontaneously when PD-L1 is genetically knocked out, an
effect mediated by T-cell responses (Fig. 1). There was,
however, a minor discrepancy between the studies. Juneja
et al. concluded that PD-L1 expression on MC38 tumor
cells was fully responsible for inhibiting antitumor T cell
responses, with no additional role for PD-L1 on host cells,
whereas the papers of Lau and ourselves both showed that
PD-L1 blocking antibody therapy of MC38 PD-L1 knockout
tumors still gives a therapeutic response. These two conclu-
sions were based on slightly different experimental setups,
which may explain the differences. In Lau et al. and our
paper, the role of host PD-L1 expression was shown by
therapeutic PD-L1 blockade in WT mice-bearing PD-L1
knockout MC38 tumors. Although in Juneja’s study, out-
growth of untreated PD-L1 knockout MC38 tumors was
much more hampered compared with the other studies, an
additional role of PD-L1 on host cells cannot be fully
excluded, since they did not treat these mice with PD-L1
blocking antibody.
The knowledge gained by the four studies contributes
greatly to our understanding of tumor immunology. By
investigating the topic from different angles and using vari-
ous techniques and pre-clinical models, the four studies
complement and validate each other. The combined out-
comes signify an important biomarker for the use of PD-1
and PD-L1 blocking antibody therapeutics. Expression of
PD-L1 within the tumor, but not necessarily on tumor cells,
is sufficient for a therapeutic effect of PD-1/PD-L1 blocking
antibodies, meaning that absence of PD-L1 expression on
tumor cells does not disqualify patients for treatment.
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Figure 1. PD-L1 expression on tumor cells and host cells jointly support tumor outgrowth. Left: in a typical immunogenic tumor, both tumor cells and intratumoral host
cells express PD-L1, resulting in progressive tumor growth. Middle: experimental genetic deletion of PD-L1 on tumor cells or the host results in reduced tumor growth,
mediated by CD8 T cells. Right: complete removal of PD-L1 expression by addition of blocking antibodies results in tumor eradication.
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